Jaime Chu, MD
- ASSOCIATE PROFESSOR | Pediatrics, Hepatology
Specialties:
Pediatrics, Liver Transplantation, Pediatric HepatologyResearch Topics:
Apoptosis/Cell Death, Biochemistry, Biomedical Sciences, Cancer, Cell Biology, Developmental Biology, Environmental Health, Fibrosis, Gastroenterology, Gene Regulation, Glycobiology, Inflammatory Bowel Disease (IBD), Metabolism, Obesity, Oncogenes, Organ Donation, Organogenesis, Patient Care, Patient Centered Outcomes Research, Pediatrics, Protein Structure/Function, Protein Translation, Regeneration, Signal Transduction, Translational Research, Transplantation, Tumor Suppressor Genes
Dr. Jaime Chu is the Associate Chief of the Division of Pediatric Hepatology and Director of the Pediatric Physician-Scientist Residency Program at the Mount Sinai Kravis Children’s Hospital and Mount Sinai’s Recanati/Miller Transplantation Institute. She received her B.A. magna cum laude from Harvard University and her M.D. from New York University School of Medicine. She completed her General Pediatrics residency training at Children’s Memorial Hospital (now Lurie Children's Hospital of Chicago) at Northwestern University in Chicago, IL and her fellowship in Pediatric Gastroenterology, Hepatology, and Nutrition both at Children’s Memorial Hospital and at the Mount Sinai School of Medicine.
Dr. Chu is a physician-scientist in pediatric hepatology. She runs an NIH-funded basic research group that focuses on how sugar metabolism pathways work together to sustain rapid cell growth in liver development and disease. The lab focuses on the role of mannose metabolism pathways in liver fibrosis. The Chu Lab capitalizes on the strength of the zebrafish as a tool to investigate metabolic mechanisms of hepatic stellatecell activation and test potential therapies to dampen the fibrogenic response. Her research has been awarded the Gilead Sciences Research Scholars Liver Disease Award, AASLD Foundation Bridge Award and R01 funding from the NIH/NIDDK to examine the role of mannose metabolism in liver fibrosis. Dr. Chu's clinical research includes participation as site PI and co-Investigator in NIH-funded consortia including a U34 Pediatric Acute Liver Failure, and other Industry-sponsored pediatric drug trials for genetic cholestatic liver disease, biliary atresia, and viral hepatitis. Dr. Chu's long-term goal is to utilize collaborative science and integrate basic and clinical research towards improving our understanding of the mechanisms underlying pediatric liver disease and to apply this knowledge towards the development of much needed therapeutic options for children with liver disease. For more information, please see the Chu Lab website: http://labs.icahn.mssm.edu/chulab/
Clinical Focus
- Acute and Chronic Liver Failure
- Autoimmune Hepatitis
- Biliary atresia
- Liver Transplant
- Metabolic liver disease
- Nonalcoholic fatty liver disease
- Portal Hypertension
Education
MD, New York University School of Medicine
BA, Harvard University
Residency, Pediatrics, Children's Memorial Hospital
Fellowship, Pediatric Gastroenterology, Children's Memorial Hospital
Fellowship, Pediatric Gastroenterology, Mount Sinai School of Medicine
-
2020
NIH / NIDDK R01 -
2019
AASLD Foundation Bridge Award -
2017
Gilead Sciences Research Scholars Program in Liver Disease Award -
2017
Art in Giving Research Scholar -
2013
NIH K08 Mentored Clinical Scientist Development Award
Liver Disease and Development, Fibrosis, and Metabolism
Dr. Chu runs an R01-funded basic research group that focuses on how sugar metabolism pathways work together to sustain rapid cell growth in liver development and disease. Dr. Chu's long-term goal is to utilize collaborative science and integrate basic and clinical research towards improving our understanding of the mechanisms underlying pediatric liver disease and to apply this knowledge towards the development of much needed therapeutic options for children with liver disease. For more information, please see the Chu Lab website: http://labs.icahn.mssm.edu/chulab/
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Chu did not report having any of the following types of financial relationships with industry during 2019 and/or 2020: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.